Relmada Therapeutics, Inc. RLMD R3KPHARMA

Q: What is the current share price of Relmada Therapeutics, Inc. (RLMD)?

As of 2026-09-19 21:16 PDT, Relmada Therapeutics, Inc. (RLMD) trades at $4.25 on NasdaqCM. Its 52-week range is $0.57 to $7.86.

Q: What is the market capitalisation of RLMD?

Relmada Therapeutics, Inc. (RLMD) has a market capitalisation of $453.35M on NasdaqCM.

Q: What is the P/E ratio of RLMD?

RLMD trades at a trailing price-to-earnings (P/E) ratio of -4.67. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.41.

Q: What is the return on equity (ROE) of RLMD?

RLMD has a return on equity (ROE) of -55.66%. Its return on capital employed (ROCE) is -67.49%.

Q: Is RLMD a good stock to buy?

This page provides a data-driven analysis of Relmada Therapeutics, Inc. (RLMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.relmada.com

Company Profile ↓

$4.25

+648.24% 1Y

Mkt Cap$453.35M

P/E-4.67

P/B0.41

52W High$7.86

52W Low$0.57

Book Value$10.15

EPS (TTM)$-0.91

Company Overview

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.10.

Growth & Price Performance

Stock Price Performance

1 Year:	+648.24%
6 Months:	-40.73%
3 Months:	-25.70%
1 Month:	-13.97%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 50% of range

$0.57 $7.86

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
Death Cross5d ago
RSI (14)32.46 · Neutral

Price Performance

1M-13.97%

3M-25.70%

6M-40.73%

1Y+648.24%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

Trading 45.9% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-4.67

Industry PE

24.83

Forward P/E

-10.37

PEG Ratio

Book Value

$10.15

Price to Book

0.41

P/S

EV/EBITDA

4.33

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

Profit 5Y

Revenue (YoY)

Earnings (YoY)

Profitability & Returns

ROCE

-67.49%

ROE

-55.66%

ROA

-32.39%

Profit Margin

0.00%

Op Margin

0.00%

Gross Margin

0.00%

EPS (Latest Qtr)

$-0.11

EPS (TTM)

$-0.91

Balance Sheet & Liquidity

Debt/Equity

0.10

Quick Ratio

29.34

Current Ratio

29.52

Debt

Total Assets

$219.06M

Current Assets

$235.34M

Working Capital

$87.55M

Ownership

Promoter Holding

3.23%

Chg in Prom Hold

0.38%

FII / Inst Holding

94.64%

Chg in FII Hold

0.07%

Financial Snapshot

Enterprise Value

$453.35M

Total Revenue (TTM)

EBITDA

$-13.86M

Free Cash Flow

$-23.65M

Operating Cash Flow

$-45.99M

Shares Outstanding

106.67M

Gross Margin

0.00%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	RLMD Relmada Therapeutics, Inc. R3KPHARMA	4.25	-4.67	$453.35M	0.00%	-67.49%	-55.66%	-	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Feb 2014	Mar 2014	Sep 2014	Dec 2014	Mar 2015	Sep 2015	Dec 2015	Mar 2016	Sep 2016	Dec 2016	Mar 2017	Sep 2017	Dec 2017	Mar 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	682	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	18.22M	10.22M	10.33M	20.33M	19.46M	-
Operating Income	-3.12K	-711.90K	-3.72M	-4.38M	-4.58M	-4.63M	-5.72M	-2.75M	-1.62M	-1.54M	-2.28M	-980.86K	-1.46M	-2.55M	-2.41M	-3.48M	-2.70M	-4.14M	-3.71M	-9.97M	-12.76M	-17.18M	-22.41M	-26.46M	-42.65M	-38.30M	-45.51M	-38.74M	-28.15M	-26.03M	-22.69M	-22.99M	-18.82M	-23.01M	-18.22M	-10.22M	-10.33M	-20.33M	-19.46M	-15.01M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-18.22M	-10.22M	-10.33M	-20.33M	-19.46M	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-17.56M	-9.87M	-10.09M	-19.87M	-19.05M	-
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-	6.49M	-29.84M	5.46M	-2.46M	4.66M	-2.46M	-1.86M	-1.64M	-1.03M	-1.98M	-981.69K	-1.43M	-3.20M	-3.38M	-7.13M	-2.69M	-4.12M	-3.67M	-10.67M	-11.12M	-16.90M	-22.22M	-26.55M	-42.61M	-39.75M	-39.93M	-39.42M	-26.32M	-25.30M	-22.00M	-21.83M	-17.77M	-21.73M	-17.56M	-9.87M	-10.09M	-19.87M	-19.05M	-12.91M
Diluted EPS	-	0.42	-3.66	0.40	-0.23	0.36	-0.22	-0.15	-0.14	-0.09	-0.16	-	-0.11	-	-	-0.28	-	-	-	-	-	-	-	-1.56	-2.44	-	-1.33	-1.31	-0.87	-0.84	-0.73	-0.72	-0.59	-0.72	-0.58	-0.30	-0.30	-	-0.22	-0.11
R&D Expense	-	-215.79K	718.97K	2.09M	2.27M	2.87M	2.12M	609.12K	364.15K	254.10K	490.69K	165.75K	150.72K	1.67M	1.42M	1.26M	1.28M	3.07M	1.89M	4.51M	5.32M	11.24M	14.02M	17.33M	33.99M	25.01M	30.91M	30.53M	15.86M	13.74M	10.45M	13.31M	10.72M	11.15M	11.95M	2.82M	4.04M	-	8.09M	8.39M

Profit & Loss (Annual)

Figures in USD.

Metric	Aug 2012	Aug 2013	Dec 2013	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	7.94K	5.13K	-	-	-	-	-	-	-	-	-	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	2.14K	1.09K	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	161.25M	103.70M	83.89M	59.10M
Operating Income	-12.05K	-45.02K	-6.77M	-17.10M	-16.22M	-7.22M	-6.92M	-12.73M	-15.11M	-60.84M	-	-161.25M	-103.70M	-83.89M	-59.10M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-161.25M	-103.70M	-83.89M	-59.10M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-157.04M	-98.79M	-79.98M	-57.39M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-12.05K	-45.02K	-19.87M	-20.80M	-2.97M	-6.29M	-8.96M	-17.32M	-15.01M	-59.46M	-	-157.04M	-98.79M	-79.98M	-57.39M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-5.30	-3.28	-2.65	-1.45
R&D Expense	-	-	5.25M	7.87M	6.21M	1.29M	2.94M	7.02M	7.86M	35.97M	90.62M	113.32M	54.81M	46.18M	26.88M

Balance Sheet (Annual)

Figures in USD.

Metric	Aug 2011	Aug 2012	Dec 2012	Aug 2013	Dec 2013	Jun 2014	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Dec 2018	Jun 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	18.35K	-	20.01K	-	25.76M	24.39M	10.24M	2.84M	3.05M	-	10.22M	117.14M	118.19M	-	152.91M	97.55M	45.82M	94.00M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	152.87M	97.51M	45.80M	93.98M
Cash & Equivalents	-	-	1.77M	-	3.52M	25.56M	22.47M	8.50M	1.71M	2.24M	2.43M	9.22M	36.28M	2.50M	-	5.40M	4.09M	3.86M	3.50M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	86.38K	512.43K	0	-	-
Total Liabilities	-	-	-	-	-	26.87M	15.58M	3.20M	1.38M	8.56M	-	2.61M	1.46M	12.60M	-	12.47M	12.19M	10.30M	7.49M
Current Liabilities	-	7.00K	-	33.67K	-	26.77M	15.58M	3.06M	1.38M	5.90M	-	2.61M	1.46M	12.60M	-	12.47M	12.19M	10.29M	6.43M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Equity	9.91K	11.36K	-3.71M	-13.66K	-17.95M	-1.11M	8.81M	7.04M	1.46M	-5.51M	-	7.61M	115.68M	105.58M	-	140.44M	85.36M	35.52M	86.51M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	30.10M	30.10M	30.17M	73.33M

Cash Flows (Annual)

Figures in USD.

Metric	Aug 2012	Aug 2013	Dec 2013	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-7.57K	-11.86K	-2.24M	-16.23M	-13.14M	-6.47M	-6.00M	-10.50M	-12.09M	-27.81M	-	-103.80M	-51.66M	-51.76M	-45.79M
Investing Cash Flow	-	-1.80K	-8.87K	-23.33K	-562.26K	-49.69K	-12.39K	-	-80.16M	-34.45M	-	19.73M	50.45M	51.56M	-48.14M
Financing Cash Flow	13.50K	20.00K	4.00M	13.16M	-263.75K	-273.67K	6.54M	17.48M	126.11M	28.47M	-	45.02M	-98.46K	-40.34K	93.56M
Capital Expenditure	-	1.80K	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow	-	-10.06K	-	-	-	-	-	-	-	-	-	-103.80M	-51.66M	-51.76M	-45.79M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-39.05M	-1.30M	-234.54K	-360.49K

Ratios (Annual)

Figures in %.

Metric	Aug 2012	Aug 2013	Dec 2013	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	27.0%	21.3%	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-151.8%	-877.7%	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Margin %	-151.8%	-877.7%	-	-	-	-	-	-	-	-	-	-	-	-	-
ROE %	-106.1%	329.6%	110.7%	-236.1%	-42.2%	-430.5%	162.5%	-227.5%	-13.0%	-56.3%	-	-111.8%	-115.7%	-225.2%	-66.3%
ROCE %	-106.1%	329.6%	-	-194.1%	-225.7%	-494.3%	242.2%	-167.2%	-13.1%	-57.6%	-	-114.8%	-121.5%	-236.1%	-67.5%

Shareholding Pattern

Insiders

3.23%

Institutions

94.64%

Public Float

97.79%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	75.07%	7.43M	$30.60M
2	Squadron Capital Management LLC	74.29%	7.35M	$30.28M
3	Venrock Adviser, LLC	69.18%	6.84M	$28.20M
4	Spruce Street Capital LP	64.60%	6.39M	$26.33M
5	Adage Capital Partners GP L.L.C.	48.14%	4.76M	$19.62M
6	Vanguard Capital Management LLC	45.08%	4.46M	$18.38M
7	Jones Hill Capital LP	36.94%	3.66M	$15.06M
8	Orbimed Advisors LLC.	36.70%	3.63M	$14.96M
9	State Street Corporation	25.45%	2.52M	$10.37M
10	Jupiter Topco LLC	-	11.16M	$46.00M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for RLMD

Google News ue, 25 Aug 2026

Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOSlZKR1pvWU5WSFR0QWdWUExHNldrSEhYeUF2Rk1ZakNmekRaY2ZodWh1bURhOHZvam1odWczcDg0RW9CeVR0UXVMNzdrRi0weHJGTlVpdVdtVTE3QUxmUHlKcXZUM21lWDRfUUJrU3dvd2FxQ0hFRm83QXA1bW5hcWhMQmx2Z0FaS282dj…

Google News ue, 01 Sep 2026

Senior managers will hold one-on-one meetings in Boston at a Wells Fargo healthcare conference Sept. 8-10. - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOa0xjWlI3R0VQVHZSRWVfbWY5TXVhWGV1MURCUXlBbGNuRnRHdmkyMzVZM0VvLVVEcU14RUM0SVozM0ExZlRoU1UyVm9BR0duSUJqVk56dVlkNVhGQ0NLNGJJUGRNd21FSEYyejlXRlRoVXhaU01mZ2dkYW8tM2FtQVNiVDJ0ZjQ4bnNfdk…

Google News Fri, 26 Jun 2026

RLMD Forecast — Price Target — Prediction for 2027 - tradingview.com

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9FLVBENVVfWVlqbkg4NVoyakdnS1RJcVlWdTgxQjJJM3Fvbm03NnluVlJEY2JwdFNmRThWclJvWU9KeUZjR20xNzVqUjVlN0ltTHhwV2NlQV9uck93TnUta1RUSHFIek5MR1A2LUV2MUNlTkxIa2tLSDh3?oc=5" target="_blank">RLM…

Google News Mon, 09 Mar 2026

RLMD Stock Soars Pre-Market: Phase 2 Bladder Cancer Trial Data Impresses Investors - Stocktwits

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxQbTN5NWg1U3NPN21OdFJZQW4yall2SXd5Zi1abmF2WWxFMWVQYjA1MFlFZDU3cGkzUnktc1gyQlM0S0RKYUp0LWZyb05Vd2R5dERsODktcF84aXhSMjFxemdjUlM0ejluRXV1dktTVHRYbUtpMVpEWFJta1BZcmhWOWZuTm9ZeTh3NHVfV2…

Google News Wed, 22 Apr 2026

Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect? - qz.com

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNYWdLdG5pQUtrQW1mUHF1ODRSWFJTS2JTOTNxU0NveGtvM2drazdxYTJHcDBoanVKUTlGeTRYOE5vTWFHUVBLSjVzWU5qWEx2a1R1Ykc1N2JNMVFJdEpjYkJtRklQLTlDUXVIejJCWDd3SldPWTgtcFpRbkdYUy13TkpDUi0wVDFIVXF4ZG…

Google News hu, 28 May 2026

RLMD - Relmada Therapeutics Inc Stock Price and Quote - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5VWk1IQlVqUmZuLXE3TEV5amFUUjlwUVZoMjJhcEZlLVlUR2JVaDBPekhBVTVNUDltb3FicnQwQzZka3BBY2c?oc=5" target="_blank">RLMD - Relmada Therapeutics Inc Stock Price and Quote</a>  <fo…

RLMD — Frequently Asked Questions

What is the current share price of Relmada Therapeutics, Inc. (RLMD)?

As of 2026-09-19 21:16 PDT, Relmada Therapeutics, Inc. (RLMD) trades at $4.25 on NasdaqCM. Its 52-week range is $0.57 to $7.86.

What is the market capitalisation of RLMD?

Relmada Therapeutics, Inc. (RLMD) has a market capitalisation of $453.35M on NasdaqCM.

What is the P/E ratio of RLMD?

RLMD trades at a trailing price-to-earnings (P/E) ratio of -4.67. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.41.

What is the return on equity (ROE) of RLMD?

RLMD has a return on equity (ROE) of -55.66%. Its return on capital employed (ROCE) is -67.49%.

Is RLMD a good stock to buy?

This page provides a data-driven analysis of Relmada Therapeutics, Inc. (RLMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Relmada Therapeutics, Inc. RLMD R3KPHARMA

Company Overview

Why Investors Should Care

Growth & Price Performance

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now - finance.yahoo.com

Senior managers will hold one-on-one meetings in Boston at a Wells Fargo healthcare conference Sept. 8-10. - Stock Titan

RLMD Forecast — Price Target — Prediction for 2027 - tradingview.com

RLMD Stock Soars Pre-Market: Phase 2 Bladder Cancer Trial Data Impresses Investors - Stocktwits

Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect? - qz.com

RLMD - Relmada Therapeutics Inc Stock Price and Quote - Finviz

RLMD — Frequently Asked Questions

What is the current share price of Relmada Therapeutics, Inc. (RLMD)?

What is the market capitalisation of RLMD?

What is the P/E ratio of RLMD?

What is the return on equity (ROE) of RLMD?

Is RLMD a good stock to buy?

Explore More